Diabetomics Inc, changes name to Modality Dx amid new innovation and expansion of molecular Signature diagnosis products
PRESS RELEASE
Porltand, OR, June 17 –Diabetomics has been rebranded Modality Dx. Founded by Dr. Srinivasa Nagalla, Modality Dx is an innovator in rapid test technologies for risk assessment and diagnosis in maternal health, diabetes and autoimmune disease.
“Throughout my career, I’ve seen firsthand the great need for more preventive healthcare solutions,” said Dr. Nagalla. “Too often doctors see patients after disease has already taken hold. My goal is to develop diagnostic tools that can assist in prevention and early intervention.”
Modality Dx has developed products that can identify molecular Signatures, provide rapid diagnostic testing, smart device technology and oral fluid technology.
Robert Gootee, Board Chair of Modality Dx, said “The goal of our research is to develop products that help healthcare professionals identify and treat disease early and accurately, thus enabling them to focus on effective disease prevention.”
Currently, Modality Dx holds patents for rapid test products that enable disease diagnosis in maternal health, diabetes and rheumatoid arthritis. These patented science and technology products enhance the measurement of treatment efficacy, thus improving the pharmaceutical industry’s ability to identify precision targets that support drug development.
About Modality Dx
Modality Dx, a privately-held Oregon-based company founded in 2010, is focused on the rapid diagnosis of disease in the maternal health, diabetes and autoimmune sectors. Through science and business excellence, they are pioneering a quantitative precision-based approach to diseases diagnosis and treatment.
Contact information
Katie Paullin
503-952-5207
Katie.paullin@modalitydx.com
Diabetomics Inc, changes name to Modality Dx amid new innovation and expansion of molecular Signature diagnosis products
Modality DxPRESS RELEASE Porltand, OR, June 17 –Diabetomics has been rebranded Modality Dx. Founded by Dr….
Diabetomics is partnering with EU consortium project EDENT1FI to introduce innovative rapid point-of-care tests for Type 1 diabetes screening.
Modality Dxhttps://www.edent1fi.eu/our-partners EDENT1FI
Five landmark clinical studies were published on glycosylated fibronectin as a new biomarker and rapid point-of-care test for risk assessment of preeclampsia
Modality DxSokratous, N., Wright, A., Syngelaki, A., Kakouri, E., Laich, A. and Nicolaides, K.H. (2023), Screening…
Diabetomics to present landmark clinical studies for 1st trimester screening and aid-in-diagnosis of preeclampsia at the 20th World congress in fetal medicine, June 25-29th Valencia, Spain.
Modality DxSerum glycosylated fibronectin in 1st trimester prediction of preterm preeclampsia Daljit Sahota (Hong Kong) Serum…
Publication of rapid point-of-care test for detection of rheumatoid arthritis
Modality DxDiabetomics has developed the first rapid point-of-care test for the autoimmune biomarker anti-citrullinated albumin (ACA)….
Regulatory approvals for Diabetomics’ rapid point-of-care tests for detection of glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), and insulin autoantibodies
Modality DxDiabetomics obtains CE-IVD Mark on glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2) and insulin…
FDA issues Emergency Use Authorization for the oral fluid rapid test for SARS-CoV-2 antibodies, the CovAbTM SARS-CoV-2 Ab Test
Modality DxOn June 4, 2021 the Food and Drug Administration (FDA) issued an Emergency Use Authorization…
Publication of Rapid Point-of-Care Test for Determination of C-Peptide Levels
Modality DxDiabetomics developed the first rapid point-of-care test for C-peptide estimation. The Insudex® C-peptide POC test has…
Regulatory approvals
Modality DxInsudex GAD65 point-of care test for rapid assessment of GAD65 autoantibodies is CE marked.
A Landmark Lumella Preeclampsia point-of-care test study published in British Journal of Obstetrics & Gynecology.
Modality DxA large, independent and prospective study in a low-resource setting demonstrated Lumella Preeclampsia rapid point-of-care…
Publication of Lumella Preeclampsia test for short-term prediction of preeclampsia.
Modality DxThe study shows Lumella PE test has the best performance for short-term prediction of preeclampsia…
Diabetomics launches Lumella point-of-care test in India
Modality Dxbiospectrumindia.com
Regulatory approvals
Modality DxLumella point-of care test for rapid assessment of Preeclampsia product is CE marked
Diabetomics inauguration of its manufacturing facility in India
Modality Dxthisweekindia.news
World’s first non-invasive test for diabetes coming up in Medak, Hyderabad
Modality DxETHealthWorld.com
Hillsboro company unveils new test to detect common prenatal problem in early stages
Modality DxPortland Business Journal
Early Preeclampsia Detection Test Under Development
Modality DxMedical Professionals Reference
Diabetomics Unveils New Test for the Early Detection, Assessment, and Monitoring of Preeclampsia
Modality DxPress Release
Maternal serum glycosylated fibronectin as a point-of-care biomarker for assessment of preeclampsia
Modality DxAmerican Journal of Obstetrics & Gynecology
Diabetomics paper on first trimester detection of gestational diabetes published in ACOG journal
Modality DxObstetrics & Gynecology
Diabetomics receives patent on non-invasive salivary diagnostics for prediabetes and diabetes
Modality DxUS Patent
Gestational diabetes early detection press
Modality DxClinical Advisor: Biomarker may ID gestational diabetes risk
Diabetomics conducts a national symposium on Autoimmune Diabetes Diagnosis and Interventions
Modality DxAutoimmune Diabetes Symposium
First-trimester Maternal Serum Biomarkers for Prediction of Gestational Diabetes
Modality DxADA Scientific Sessions
Non-invasive Salivary Protein Glycosylation as a Short Term Glycemic Index
Modality DxADA Scientific Sessions